-
公开(公告)号：US20210277000A1
公开(公告)日：2021-09-09
申请号：US17076891
申请日：2020-10-22
Applicant: SciFluor Life Sciences, Inc.
Inventor： Ben C. ASKEW , Takeru FURUYA
IPC: C07D471/04 , A61P1/00 , A61P27/00
Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
-
公开(公告)号：US10301307B2
公开(公告)日：2019-05-28
申请号：US15700351
申请日：2017-09-11
Applicant: SciFluor Life Sciences, Inc.
Inventor： Ben C. Askew , Takeru Furuya
IPC: C07D471/04 , A61P1/00 , A61P27/00
Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
-
公开(公告)号：US10155758B2
公开(公告)日：2018-12-18
申请号：US15715368
申请日：2017-09-26
Applicant: SciFluor Life Sciences, Inc.
Inventor： Ben C. Askew , Richard W. Heidebrecht , Takeru Furuya , Mark E. Duggan
IPC: C07D471/04 , A61K31/444 , A61K45/06 , A61K31/4375 , A61K31/513
Abstract: The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.
-
公开(公告)号：US10118929B2
公开(公告)日：2018-11-06
申请号：US15498736
申请日：2017-04-27
Applicant: SciFluor Life Sciences, Inc.
Inventor： Takeru Furuya , Ben C. Askew
IPC: C07D487/04 , C07D235/30 , C07D233/36 , C07D403/12 , C07D413/12 , C07D471/04 , C07D401/06 , C07D401/12
Abstract: The present disclosure relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present disclosure also relates to pharmaceutical compositions containing the fluorinated compounds of the disclosure, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
-
5.发明授权Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives 有权氟化3-（2-氧代-3-（3-芳基丙基）咪唑烷-1-基）-3-芳基丙酸衍生物公开(公告)号：US09593114B2
公开(公告)日：2017-03-14
申请号：US15000311
申请日：2016-01-19
Applicant: SciFluor Life Sciences, Inc.
Inventor： Ben C. Askew , Richard W. Heidebrecht , Takeru Furuya , Mark E. Duggan
IPC: C07D471/04 , A61K31/444 , A61K45/06 , A61K31/4375 , A61K31/513
CPC classification number: C07D471/04 , A61K31/4375 , A61K31/444 , A61K31/513 , A61K45/06
Abstract: The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.
Abstract translation: 本发明涉及氟化化合物及其作为整联蛋白受体拮抗剂的用途。 描述了新的氟化3-（2-氧代-3-（3-芳基丙基）咪唑烷-1-基）-3-芳基丙酸衍生物及其药学上可接受的盐或溶剂合物及其用途。
-
Patent Agency Ranking
公开(公告)号：US20210163473A1
公开(公告)日：2021-06-03
申请号：US16991138
申请日：2020-08-12
Applicant: SciFluor Life Sciences, Inc.
Inventor： Ben C. ASKEW , Richard W. HEIDEBRECHT , Takeru FURUYA , Mark E. DUGGAN , D. Scott EDWARDS
IPC: C07D471/04 , A61K31/4375 , A61K45/06 , A61K31/444 , A61K31/506 , A61K9/00 , A61K31/4709
Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
-
公开(公告)号：US10752625B2
公开(公告)日：2020-08-25
申请号：US16288309
申请日：2019-02-28
Applicant: SciFluor Life Sciences, Inc.
Inventor： Takeru Furuya
IPC: C07D471/04 , C07D401/06
Abstract: The present application relates to methods of preparing a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof.
-
公开(公告)号：US10253025B2
公开(公告)日：2019-04-09
申请号：US15941604
申请日：2018-03-30
Applicant: SciFluor Life Sciences, Inc.
Inventor： Takeru Furuya
IPC: C07D471/04 , C07D403/14 , C07D401/06
Abstract: The present application relates to methods of preparing a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof.
-
公开(公告)号：US10106537B2
公开(公告)日：2018-10-23
申请号：US15633946
申请日：2017-06-27
Applicant: SciFluor Life Sciences, Inc.
Inventor： Ben C. Askew , Richard W. Heidebrecht , Takeru Furuya , Mark E. Duggan , D. Scott Edwards
IPC: C07D471/04 , A61K31/4375 , A61K31/444 , A61K31/506
Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
-
10.发明授权公开(公告)号：US09556114B2
公开(公告)日：2017-01-31
申请号：US14566167
申请日：2014-12-10
Applicant: SciFluor Life Sciences, Inc.
Inventor： Mark E. Duggan , Takeru Furuya , D. Scott Edwards , Ajay Purohit
IPC: A61K51/00 , A61M36/14 , C07C271/28 , A61K51/04 , C07B59/00 , C07F15/00 , C07D213/75 , C07F5/02
CPC classification number: C07C271/28 , A61K51/0406 , A61K51/0455 , C07B59/001 , C07B59/002 , C07B2200/05 , C07D213/75 , C07F5/025 , C07F15/006
Abstract: The invention relates to fluorinated compounds and their use as anti-epileptic, muscle-relaxing, fever-reducing and peripherally analgesically acting medications and as imaging agents. Novel fluorinated 2-amino-4-(benzylamino)phenyl carbamate derivatives of ezogabine and pharmaceutically acceptable salts or solvates thereof and their use are described.
Abstract translation: 本发明涉及氟化合物及其作为抗癫痫，肌肉松弛，发烧减少和外周镇痛作用药物和作为成像剂的用途。 描述了依佐他布的新型氟化2-氨基-4-（苄基氨基）苯基氨基甲酸酯衍生物及其药学上可接受的盐或溶剂合物及其用途。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.019 seconds)
